Nadav Kidron - Oramed Pharmaceuticals President CEO, Director
| ORMP Stock | 8.85 0.23 2.67% |
CEO
Mr. Nadav Kidron is an President, Chief Executive Officer, Director of the Company. He was appointed President, Chief Executive Officer and became a director in March 2006. He is also a director of Israel Advanced Technology Industries organization, and until 2016 was a director of Entera. In 2009, he was a fellow at the Merage Foundation for U.S.Israel Trade Programs for executives in the life sciences field. From 2003 to 2006, he was the managing director of the Institute of Advanced Jewish Studies at Bar Ilan University. From 2001 to 2003, he was a legal intern at Wine, Mishaiker Ernstoff Law Offices in Jerusalem, Israel since 2006.
| Age | 42 |
| Tenure | 18 years |
| Professional Marks | MBA |
| Phone | 844-967-2633 |
| Web | http://www.oramed.com |
Oramed Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (26.77) % which means that it has lost $26.77 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (78.51) %, meaning that it generated substantial loss on money invested by shareholders. Oramed Pharmaceuticals' management efficiency ratios could be used to measure how well Oramed Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | CEO Age | ||
| Israel Keren | Azrieli Group | 76 | |
| Ehud Arnon | Israel Discount Bank | 65 | |
| Asher Grinbaum | ICL Israel Chemicals | 67 | |
| Nissim Adar | ICL Israel Chemicals | 63 | |
| Eyal Chenkin | Azrieli Group | 47 | |
| Lisa Haimovitz | ICL Israel Chemicals | 51 | |
| Yuval Bronstein | Azrieli Group | 47 | |
| Bezhalel Machlis | Elbit Systems | 60 | |
| Daniel Tsiddon | Bank Leumi Le Israel | 59 | |
| Hanan Friedman | Bank Leumi Le Israel | 52 | |
| Eyal Hankin | Azrieli Group | N/A | |
| Lilach Toplinsky | Israel Discount Bank | 48 | |
| Esther Deutsch | Israel Discount Bank | 57 | |
| Charles Weidhas | ICL Israel Chemicals | 57 | |
| Rakefet RussakAminoach | Bank Leumi Le Israel | 51 | |
| Guy Eristoff | Tower Semiconductor | 55 | |
| Stefan Borgas | ICL Israel Chemicals | 50 | |
| Barak Eilam | Nice | 47 | |
| Arnon Toren | Azrieli Group | 60 | |
| Craig Costigan | Nice | 62 | |
| Avner Mendelson | Bank Leumi Le Israel | 48 | |
Management Performance
| Return On Equity | -78.51 | |||
| Return On Asset | -26.77 |
Oramed Pharmaceuticals Leadership Team
Elected by the shareholders, the Oramed Pharmaceuticals' board of directors comprises two types of representatives: Oramed Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oramed. The board's role is to monitor Oramed Pharmaceuticals' management team and ensure that shareholders' interests are well served. Oramed Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oramed Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ronald Law, Chief Strategy Officer | ||
| Miriam Kidron, Chief Scientific Officer, Director | ||
| Xiaopeng Li, Independent Director | ||
| Leonard Sank, Independent Director | ||
| Nadav Kidron, President CEO, Director | ||
| Mark Hasleton, Vice President - Business Development | ||
| Xiaoming Gao, Director | ||
| Kevin Rakin, Chairman of the Board, Independent Director | ||
| David Slager, Independent Director | ||
| Hilla Eisenberg, CFO, Treasurer, Secretary | ||
| Aviad Friedman, Independent Director | ||
| Joshua Hexter, COO, Vice President - Business Development | ||
| Avi Gabay, CFO, Treasurer, Secretary |
Oramed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oramed Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -78.51 | |||
| Return On Asset | -26.77 | |||
| Operating Margin | (584.92) % | |||
| Current Valuation | 156.33 M | |||
| Shares Outstanding | 17.38 M | |||
| Price To Book | 866.13 X | |||
| Revenue | 2.64 M | |||
| Gross Profit | 2.54 M | |||
| EBITDA | (15.43 M) | |||
| Net Income | (15 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Oramed Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Oramed Pharmaceuticals' short interest history, or implied volatility extrapolated from Oramed Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oramed Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Oramed Stock refer to our How to Trade Oramed Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Oramed Stock analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities |